Eslicarbazepine acetate
Anticonvulsant medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Eslicarbazepine acetate?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy.[6][4][3]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Aptiom, Zebinix, Exalief |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~30%[5] |
Metabolism | UGT (?) |
Metabolites | Eslicarbazepine (active), glucuronides (inactive), etc. |
Elimination half-life | 10–20 hours |
Excretion | ~90% renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.164.398 |
Chemical and physical data | |
Formula | C17H16N2O3 |
Molar mass | 296.326 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
Similarly to oxcarbazepine, ESL behaves as a prodrug to (S)-(+)-licarbazepine.[7] As such, their mechanisms of action are identical.[8]